RPM Cybersecurity 2026: FDA 524B Mandates & SBOM Compliance

-
Image
The RPM Cybersecurity Shift: Navigating New FDA Mandates and Software Supply Chain Transparency in 2026 A Senior Cybersecurity Architect's Field Guide — Because "We Think We're Covered" Is No Longer Good Enough May 2026  |  20-minute read  |  Written for C-Suite, Regulatory Affairs, and QA Leadership 📋 Table of Contents The Confidence Paradox: Why 90% Confidence Masks a 50% Coverage Gap The FDA Mandate Reality: Section 524B Is Not a Suggestion Anymore RPM Cybersecurity 2026: How CMS Expansion Created a New Attack Surface SBOM in 2026: From Compliance PDF to Quality System Backbone Comparison Table: Pre-2026 vs. The 2026 Mandatory Framework ISO 14971 as Connective Tissue: Risk Management Meets the Supply Chain Real-World Scenario: How a Mature SBOM Prevented a Class I Recall FDA Inspection Readiness: What Investigators Will Look For Under CP 7382.850 What You Need to Do Right Now: A 7-Poin...
Post a Comment

Competition intensifying for diabetes subjects; Acurian

-

Competition intensifying for diabetes subjects; Acurian


Acurian, a company that specializes in patient recruiting, has reached a significant business milestone with the addition of more than 50 percent of the country's type 2 diabetes population to its database. 


Approximately 8 million of the estimated 16 million diagnosed type 2 or adult-onset diabetes are already on the company's books. The business maintains a database of almost 40 million patients in total.

According to Rick Malcolm, PhD, CEO of Acurian, "It should come as no surprise that diabetes is one of the most strong indications in our database. However, given the fierce rivalry for research participants in this therapeutic field, the fact that more than half of the nation's type 2 diabetics are present and open to learning about clinical trials is definitely important to note. 

According to him, Acurian can assist trial sponsors in gaining access to huge numbers of diabetic patients so they can successfully recruit the right subsets, such as people of color who have the disease or those who have type 1 diabetes.

Comments

Post a Comment

Popular posts from this blog

Solubility Formulas, Solubility Charts, and Drug Delivery

-
Image
The Science Behind Solubility: Solubility Formula, Solubility Chart, and Drug Delivery system In the intricate world of pharmaceuticals, understanding solubility is crucial for effective drug development and delivery. Solubility, the ability of a substance to dissolve in a solvent, plays a pivotal role in determining a drug's bioavailability, efficacy, and even its safety profile.  In this article, we will delve into the science behind solubility, exploring solubility formulas, solubility charts, and their significance in drug delivery. The Basics of Solubility: Solubility forms the foundation of drug formulation. It is governed by various factors, including the drug's molecular structure, the solvent's properties, and temperature. When a drug's solubility is low, its absorption into the bloodstream can be compromised, resulting in suboptimal therapeutic effects. To overcome this, scientists employ solubility-enhancing techniques, making solubility formulas and charts i...
Read Full Article »

EU MedTech Innovation: MDR, IVDR & 2026 EY-DG SANTE Updates

-
Image
The EU MedTech Innovation Pressure: Navigating 2026 "Crunch" and EY-DG SANTE Findings For years, the European Union was the global launchpad for EU MedTech Innovation, but recent data suggests a pivotal identity crisis is looming. A "CE Mark" was often the first major milestone for a startup before tackling the FDA. However, the tide has turned. As we move deeper into the mid-2020s, the medical technology landscape is facing a pivotal identity crisis.  The recent EY-DG SANTE study , commissioned by the European Commission, has provided the data to back up what many MedTech professionals have been whispering in boardrooms: the regulatory burden of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) is creating an "innovation drain." The Data Speaks: Key Findings from the EY-DG SANTE Study The study was designed to monitor the availability of medical devices on the EU market. The results are a wake-up call. According to the ...
Read Full Article »

​AI Solubility Prediction & 2026 Formulation Trends

-
Image
If you are a pharmacy student or a researcher in 2026, the old textbooks aren't telling you the whole story. For decades, we learned that solubility was simple: "Like dissolves like." We memorized the Noyes-Whitney equation, looked at a solubility chart , and mixed powders in a beaker. But today, that approach is obsolete. With 90% of new drug candidates classified as "poorly soluble" (BCS Class II and IV), the industry faces an "insolubility crisis." The modern lab doesn't just "dissolve" drugs; it engineers them. We use Artificial Intelligence to predict solubility limits before a molecule is even synthesized. We use lasers and supercomputers to force "brick dust" molecules into the bloodstream. This article is your guide to the New Science of Solubility . We will decode the modern math, the AI tools like FastSolv , and the breakthrough technologies like Lipid Nanoparticles (LNPs) that are redefining drug delivery in ...
Read Full Article »